Onsdag 28 Oktober | 17:15:33 Europe / Stockholm
Est. tid*
2026-08-20 - Kvartalsrapport 2026-Q2
2026-04-24 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2026-04-23 - Årsstämma
2026-03-05 - Bokslutskommuniké 2025
2025-08-21 - Kvartalsrapport 2025-Q2
2025-04-25 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2025-04-24 - Årsstämma
2025-03-06 - Bokslutskommuniké 2024
2024-08-22 - Kvartalsrapport 2024-Q2
2024-04-25 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2024-04-24 - Årsstämma
2024-03-06 - Bokslutskommuniké 2023
2023-11-17 - Extra Bolagsstämma 2023
2023-08-24 - Kvartalsrapport 2023-Q2
2023-04-21 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2023-04-20 - Årsstämma
2023-03-02 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-04-22 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2022-04-21 - Årsstämma
2022-03-03 - Bokslutskommuniké 2021
2021-08-26 - Kvartalsrapport 2021-Q2
2021-04-16 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2021-04-15 - Årsstämma
2021-03-03 - Bokslutskommuniké 2020
2020-12-02 - Extra Bolagsstämma 2020
2020-08-27 - Kvartalsrapport 2020-Q2
2020-04-09 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2020-04-08 - Årsstämma
2020-02-27 - Bokslutskommuniké 2019
2019-08-28 - Kvartalsrapport 2019-Q2
2019-04-12 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2019-04-11 - Årsstämma
2019-03-12 - Extra Bolagsstämma 2019
2019-02-28 - Bokslutskommuniké 2018
2018-08-29 - Kvartalsrapport 2018-Q2
2018-04-12 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2018-04-11 - Årsstämma
2018-03-02 - Bokslutskommuniké 2017
2017-11-09 - Extra Bolagsstämma 2017
2017-08-29 - Kvartalsrapport 2017-Q2
2017-04-12 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2017-04-11 - Årsstämma
2017-02-28 - Bokslutskommuniké 2016
2016-08-25 - Kvartalsrapport 2016-Q2
2016-04-12 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2016-04-11 - Årsstämma
2016-02-25 - Bokslutskommuniké 2015
2015-08-19 - Kvartalsrapport 2015-Q2
2015-04-10 - X-dag ordinarie utdelning HRTIS 0.00 EUR
2015-04-09 - Årsstämma
2015-02-27 - Bokslutskommuniké 2014
2014-04-23 - Kvartalsrapport 2014-Q1
2014-03-05 - Bokslutskommuniké 2013
LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriLäkemedel & Handel
Herantis Pharma är ett bioteknikbolag i klinisk fas som utvecklar sjukdomsmodifierande terapier för Parkinsons sjukdom. Bolagets ledande produkt HER-096 är en liten syntetisk kemisk peptidomimetisk molekyl utvecklad baserat på CDNF-proteinets aktiva plats. HER-096 kombinerar verkningsmekanismen för CDNF med subkutan administrering. Herantis Pharma grundades 2008 och har sitt huvudkontor i Esbo, Finland.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Herantis Pharma Plc's directed share issue and share subscription by Broadview Ventures I, LLC

2016-01-14 09:00:00
Herantis Pharma Plc's directed share issue and share subscription by Broadview Ventures I, LLC

Herantis Pharma Plc's directed share issue and share subscription by Broadview Ventures I, LLC

Herantis Pharma Plc
Stock exchange release 14 January 2016, 10:00 am

The Board of Directors of Herantis Pharma Plc has decided on a directed share issue to Broadview Ventures I, LLC based on authorization by the company's annual meeting of shareholders and according to a subscription agreement between the parties. Broadview Ventures I, LLC has fully subscribed to this share issue, total of 32,311 new shares in Herantis Pharma Plc for a subscription price of  EUR 10.00 per share.

The new shares have been registered in the Trade Register on 12 January 2016, as of which date the new shares will establish shareholder rights.

The share capital will not increase with subscriptions. The entire subscription price of EUR 323,110.00 will be entered in the invested unrestricted equity reserve of the company. As a result of the share subscriptions, the number of shares of Herantis Pharma Plc will increase to 4,118,305 shares.

The new shares will be traded on the NASDAQ OMX Helsinki Ltd's First North marketplace together with the old shares as of today, 14 January 2016.

Share information of the Herantis Pharma Plc share after the registration of the new shares:

Trading Code: HRTIS
ISIN code: FI4000087861
List: First North Helsinki
Industry: Health Care
Number of Shares: 4,118,305
Share Capital: 80,000.00 euro

Herantis Pharma Plc.
Pekka Simula
CEO

Further information:

Herantis Pharma Plc., Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 246

About Herantis Pharma Plc

Herantis Pharma Plc is a pharmaceutical company specialised in new drug research and development. The company focuses on diseases with an unmet clinical need. These diseases include for example Parkinson's disease and secondary lymphedema. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.

Distribution:

Nasdaq Helsinki
Main media
www.herantis.com